Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Exploring Myasthenia Gravis Disease with DLI's Drug Insights, Clinical Trial Management, and Product Development Services | Disease Landscape Insights

Disease Landscape Insights Logo

News provided by

Disease Landscape Insights

Oct 10, 2023, 05:45 ET

Share this article

Share toX

Share this article

Share toX

LONDON, Oct. 10, 2023 /PRNewswire/ -- Myasthenia Gravis is a neuromuscular disorder which is quite rate in nature. Epidemiology study suggests that approximately 20 in every 100,000 people are affected with the MG disease.   The prevalence of this ailment may vary among different age groups and genders, with some subgroups having a higher incidence.

Myasthenia Gravis is a chronic neuromuscular disease that typically impacts the communication between our muscles and nerves. It occurs when the immune system mistakenly targets and attacks a specific protein called acetylcholine receptor, which is essential for transmitting nerve signals to muscles. MG complications deteriorate a patient's quality of life.

Timely MG prognosis is crucial to ensure the well being of a patient. This happens only after the disease is diagnosed timely. Proper MG management necessitates effective diagnostic and treatment entities. Industry participants are striving to bring about the much-needed transformation in this vertical. Disease Landscape Insights has been helping them with MG research, treatment gaps identification, product pipeline analysis, drug development, regulatory consulting, clinical trial feasibility analysis, and overall MG clinical trial assessment.

Price and Market Access

It has also been assisting them with the formulation of ideal price and market access strategies along with product portfolio extension plans. This health consultant has also been offering pharma consulting services to the related companies to support them with new product development and post launch strategies.

What are the causes and symptoms of this disorder?

The causes of this ailment may vary based on different parameters. However, MG specialists have listed down a few significant factors leading to the onset of MG complications.  The primary ones are genetics, infections, environmental factors, unhealthy lifestyle habits, and autoimmune reactions.

Major symptoms of this disorder are body ache, fatigue, fever, shortness of breath, digestive issues, swelling, headaches, dizziness, numbness, skin changes, and mental disorders. It is crucial for patients to consult an MG neurologist if the neurological symptoms persist for a long duration.

Discover More About Pricing and Reimbursement, Epidemiology Study, and Healthcare @

Request_Myasthenia Gravis

Detection And Treatment:

MG diagnosis involves a combination of physical examinations and tests. Clinical evaluation, neurological examination, tensilon test, blood tests, electrodiagnostic tests, and certain imaging tests are conducted to identify the occurrence of this ailment.

The Myasthenia Gravis treatment landscape is vast. Treatment plans are made according to the overall health status of a patient. MG medications that are primarily prescribed include cholinesterase inhibitors, monoclonal antibodies, and immunosuppressants.  Apart from that MG therapy like IVIG therapy and physical therapy may also help in some cases.

MG surgery in the form of thymectomy involving the surgical removal of thymus gland (thymectomy) may also be recommended.

Unlock the Benefits Today! Get Started Now and Elevate Your Experience @

Checkout_Myasthenia Gravis

Final Words:

Myasthenia Gravis primarily affects the body muscles causing movement issues and other symptoms. There are cases where MG can become life-threatening, particularly when it affects the muscles responsible for breathing and swallowing. This is referred to as a myasthenic crisis, and it can result in severe respiratory distress, choking, and difficulty in maintaining adequate oxygen levels. This ailment can be triggered by various factors, including infections, medication changes, or stress. The specific treatment plan for MG is tailored to the individual's needs and the severity of their symptoms. DLI aids in the development of innovative medications that can alleviate the burden of MG symptoms. Its dedication to assisting the patients in terms of drug development is paving the way for more effective therapies. Moreover, DLI's dedication to product development services signifies a holistic approach to addressing the needs of individuals living with MG. The joint efforts between DLI and industry participants promises hope, progress, and a brighter future for the patients affected with this disorder.

Browse Through More Autoimmune Diseases Research Reports.

Related Reports:

Insights and Trends in the Global Landscape of Lung Cancer Services

The symptoms, transmission, and precautions of Monkeypox

The Myths of Pneumonia: Symptoms, Causes, and Prevention Methods

Navigating the Complex Autoimmune Disorder of Lupus

Ringworm Comprehensive Guide: Symptoms, Causes, and Treatment

Diverticulitis: A Complete Guide to the Symptoms, Causes, and Treatments

When it comes to strategic Diabetes Disease consultancy, some of the areas we assist you understand include Regulatory Insights, Disease Landscape, and Market Access Expertise.

Find treatments for HPV illness using specialized market entry strategies. FDA/EMA insights and clinical trial advice. Examine right away!

Learn about specific approaches to Pancreatic Cancer Disease market access, pricing, and reimbursement. Learn about market research and clinical trials. Change your business immediately.

Learn about KOLs, the FDA, epidemiology, price reimbursement, and more in this market report on Anemia Disease. Your trustworthy source for info on anemia. Examine right away!

Chlamydia Disease symptoms, treatment, and market research. Keep up with epidemiology research, FDA and EMA updates, and market entry tactics.

employing our tried-and-true strategy, penetrate the Ovarian Cancer Disease market. Learn to negotiate the regulatory process, discover the key opinion leaders for your product, and establish fair pricing.

Learn about Gastric Cancer Market Strategies, KOL Insights, Regulatory Updates, and Market Intelligence. Make use of our knowledge to get through challenges.

The success of the Breast Cancer market is built on FDA insights, pricing strategies, and a successful market launch. Investigate epidemiology and market intelligence to gain a competitive edge.

Find out more about Prostate Cancer Consulting, FDA-EMA Drugs, Pricing, and Regulatory Insights. Obtain an epidemiology study and market access. Rely on DLI!

FDA-EMA Approved Drugs, Disease Landscape, and Epidemiology Studies: Expert Consulting on Skin Cancer. Pricing Compensation and Market Access.

Find out more about Tonsillitis symptoms, consulting services, drug costs, FDA-approved medications, disease landscape, regulatory insights, epidemiology, and price reimbursement.

Investigate the epidemiology, prevention, and consulting services for Scrub Typhus. Discover the landscape of diseases, FDA-EMA approved medications, and more.

Discover the market insights, competitive environment, regulatory updates, and epidemiology study for lymphoma. Market entry strategy: Unlock market intelligence.

A Colorectal Cancer market entrance plan can assist you in navigating the competitive environment, getting in touch with important decision-makers, and achieving your regulatory and business objectives. To find out more, call us right away.

About Disease Landscape:  

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us:  
isease Landscape Insights LLP  
th Floor, Sr No.207, Office A H 6070 Phase 1 
Solitaire Business Hub, Viman Nagar  
Pune, Maharashtra, 411014 
Contact: +44-2038074155 
Asia Office Contact: +917447409162
Email: [email protected]    
Email: [email protected]
Blog: https://www.diseaselandscape.com/blogs  
Case Study: https://www.diseaselandscape.com/casestudies   
Pharma consulting Services  
Follow Us: LinkedIn | Twitter | Facebook

Logo: https://mma.prnewswire.com/media/2217060/4328675/Disease_Landscape_Insights_Logo.jpg

SOURCE Disease Landscape Insights

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.